The price at which imatinib has been offered for sale by Novartis around the world has caused me considerable discomfort. Pharmaceutical companies that have invested in the development of medicines should achieve a return on their investments. But this does not mean the abuse of these exclusive rights by excessive prices and seeking patents over minor changes to extend monopoly prices. This goes against the spirit of the patent system and is not justified given the vital investments made by the public sector over decades that make the discovery of these medicines possible.
"She initially was berated and belittled by university officials, including the president, Mark Yudof, and his staff and sycophants, who portrayed her (and her legal counsel, the late Jim Lord) as a lone wolf in the cheating scheme, and a traitorous ingrate for subsequently blowing the whistle and disclosing it." - Marshall Tanick remembers Jan Gangelhoff and and the U's notorious athletic cheating scandal.
1 hour ago